MedWatch

Analyst: New Eli Lilly drug doesn't throw Novo Nordisk's Ozempic curveball

Danish bank analyst Søren Løntoft from Sydbank estimates that Eli Lilly has presented a decent set of data for new drug tirzepatide, but hardly enough to outmatch Novo's Ozempic drug.

Photo: Darron Cummings/AP/Ritzau Scanpix

On Wednesday, US pharmaceutical company Eli Lilly presented another batch of decent trial results with the GIP/GLP-1 analog tirzepatide, which is comparable with Novo's semaglutide, marketed as Ozempic and Rybelsus, on several counts.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs